Preformulation studies for selection of excipients for cholinesterase inhibitor tacrine
Închide
Articolul precedent
Articolul urmator
581 4
Ultima descărcare din IBN:
2021-09-24 11:39
SM ISO690:2012
LEDEŢI, Ionuţ, ŞUTA, Lenuţa-Maria, MURARIU, Marius, CIRCIOBAN, Denisa, VLASE, Gabriela, LEDEŢI, Adriana, VLASE, Titus. Preformulation studies for selection of excipients for cholinesterase inhibitor tacrine. In: Central and Eastern European Conference on Thermal Analysis and Calorimetry, Ed. 4, 28-31 august 2017, Chişinău. Germany: Academica Greifswald, 2017, Editia 4, p. 476. ISBN 978-3-940237-47-7.
EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core
Central and Eastern European Conference on Thermal Analysis and Calorimetry
Editia 4, 2017
Conferința "Central and Eastern European Conference"
4, Chişinău, Moldova, 28-31 august 2017

Preformulation studies for selection of excipients for cholinesterase inhibitor tacrine


Pag. 476-476

Ledeţi Ionuţ1, Şuta Lenuţa-Maria1, Murariu Marius1, Circioban Denisa1, Vlase Gabriela1, Ledeţi Adriana1, Vlase Titus2
 
1 Victor Babes University of Medicine and Pharmacy, Timişoara,
2 West University of Timisoara
 
 
Disponibil în IBN: 30 octombrie 2019


Rezumat

Tacrine (IUPAC: 1,2,3,4-tetrahydroacridin-9-amine) is a chemical compound that acts as a reversible inhibitor and classical pharmacophore known as one of the main FDA approved drugs for AD [1]. Chemical structure of tacrine (1,2,3,4-tetrahydroacridin-9-amine) The selected excipients were starch, calcium lactate, lactose, mannitol, magnesium stearate, sodium carboxy-methyl-cellulose, PVP, sorbitol, talc and fumed silica. As investigation tools, FTIR spectroscopy was choose as first technique, in order to determine the compatibility of components under ambient conditions, and the results are correlated with the ones of PXRD patterns. Later, the influence of thermal stress over the stability of samples and the analysis of thermal-induced interactions was studied by using thermal analysis [2]. For the observed incompatibities, a possible mechanism of interaction between levodopa and excipients was discussed.